Dolan G, Benson G, Duffy A, et al. Haemophilia B: where are we now and what does the future hold? Blood Rev. 2018;32:52–60.

Article  CAS  PubMed  Google Scholar 

Hart DP, Matino D, Astermark J, et al. International consensus recommendations on the management of people with haemophilia B. Ther Adv Hematol. 2022;13:1–22.

Article  Google Scholar 

Nazeef M, Sheehan JP. New developments in the management of moderate-to-severe hemophilia B. J Blood Med. 2016;7:27–38.

PubMed  PubMed Central  Google Scholar 

Mahlangu JN. Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B. Ther Adv Hematol. 2018;9(11):335–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016;388(10040):187–97.

Article  PubMed  Google Scholar 

Swedish Orphan Biovitrum AB. ALPROLIX (eftrenonacog alfa): EU summary of product characteristics; 2021. https://www.ema.europa.eu/. Accessed 22 Mar 2023.

Bioverativ Therapeutics Inc. ALPROLIX [coagulation factor IX (recombinant), Fc fusion protein], lyophilized powder for solution for intravenous injection: US prescribing information; 2020. https://dailymed.nlm.nih.gov/dailymed/. Accessed 22 Mar 2023.

Hoy SM. Eftrenonacog alfa: a review in haemophilia B. Drugs. 2017;77(11):1235–46.

Article  CAS  PubMed  Google Scholar 

Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369(24):2313–23.

Article  CAS  PubMed  Google Scholar 

Fischer K, Kulkarni R, Nolan B, et al. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study. Lancet Haematol. 2017;4(2):e75–82.

Article  PubMed  Google Scholar 

Nolan B, Klukowska A, Shapiro A, et al. Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B. Blood Adv. 2021;5(13):2732–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pasi KJ, Fischer K, Ragni M, et al. Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: results from the B-YOND extension study. Haemophilia. 2020;26(6):e262–71.

Article  CAS  PubMed  Google Scholar 

European Medicines Agency. ALPROLIX (eftrenonacog alfa): EU public assessment report; 2016. http://www.ema.europa.eu/. Accessed 22 Mar 2023.

Wyrwich KW, Krishnan S, Auguste P, et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia. 2016;22(6):866–72.

Article  CAS  PubMed  Google Scholar 

Astermark J, Hermans C, Ezzalfani M, et al. rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires. Haemophilia. 2022;28(1):18–26.

Article  CAS  PubMed  Google Scholar 

Shapiro AD, Kulkarni RD, Ragni MV, et al. Post hoc longitudinal assessment of efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B. Blood Adv. 2023. https://doi.org/10.1182/bloodadvances.2022009230.

Article  PubMed  Google Scholar 

Chowdary P, Holmström M, Mahlangu JN, et al. Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: data on safety and effectiveness from phase 3 pivotal studies. Res Pract Thromb Haemost. 2022;6: e12760.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Powell JS, Apte S, Chambost H, et al. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study. Br J Haematol. 2015;168(1):124–34.

Article  CAS  PubMed  Google Scholar 

Glosli H, Ranta S, Allsup D, et al. Interim analysis from B-MORE, a 24-month prospective, multicentre, non-interventional study on effectiveness and usage of recombinant factor IX Fc (rFIXFc) in haemophilia B [abstract no. PB1153]. In: International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress; 2022.

Chambost H, Repesse Y, Genre Volot F, et al. Final data from B-SURE, a French multicentre study in patients with haemophilia B, evaluating real-world usage and effectiveness of recombinant factor IX FC (rFIXFc) [abstract no. PO068]. Haemophilia. 2023;29(S1):57–8.

Google Scholar 

Castet S, Chambost H, Fouassier M, et al. Real-world effectiveness and usage of recombinant factor IX Fc fusion protein (rFIXFc) for management of major/minor surgeries in patients with haemophilia B (HB) in France: results from the ongoing B-SURE study [abstract no. ABS175]. Haemophilia. 2021;27(Suppl 2):115–6.

Google Scholar 

Bidlingmaier C, Heller C, Langer F, et al. Final data from the PREVENT study evaluating real-world usage and effectiveness of a recombinant factor VIII Fc and recombinant factor IX Fc in haemophilia A or B in Germany [abstract no. PO051]. Haemophilia. 2023;29(S1):48–9.

Google Scholar 

Shapiro A, Chaudhury A, Wang M, et al. Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years. Haemophilia. 2020;26(6):975–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brennan Y, Parikh S, McRae S, et al. The Australian experience with switching to extended half-life factor VIII and IX concentrates: on behalf of the Australian Haemophilia Centre Directors’ Organisation. Haemophilia. 2020;26(3):529–35.

Article  PubMed  Google Scholar 

Shrestha A, Su J, Li N, et al. Physical activity and bleeding outcomes among people with severe hemophilia on extended half-life or conventional recombinant factors. Res Pract Thromb Haemost. 2021;5(1):94–103.

Article  CAS  PubMed  Google Scholar 

O’Donovan M, Singleton E, Roche S, et al. Single centre, real-world experience of perioperative rFIXFc use in adult patients with haemophilia B undergoing major and minor surgery. Haemophilia. 2021;27(6):e690–7.

Article  CAS  PubMed  Google Scholar 

European Medicines Agency. ALPROLIX (eftrenonacog alfa): EU public assessment report–variation; 2019. https://www.ema.europa.eu/en/medicines/human/EPAR/alprolix. Accessed 22 Mar 2023.

Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1–158.

Article  PubMed  Google Scholar 

CSL Behring GmbH. IDELVION (albutrepenonacog alfa) powder and solvent for solution for injection: EU summary of product characteristics; 2021. https://www.ema.europa.eu/en/medicines/human/EPAR/idelvion. Accessed 22 Mar 2023.

CSL Behring. IDELVION [coagulation factor IX (recombinant), albumin fusion protein]: US prescribing information; 2021. https://dailymed.nlm.nih.gov/. Accessed 22 Mar 2023.

Novo Nordisk A/S. Refixia powder and solvent for solution for injection: EU summary of product characteristics; 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/refixia. Accessed 22 Mar 2023.

Novo Nordisk. REBINYN® [coagulation factor IX (recombinant), glycopegylated] lyophilized powder for solution for intravenous injection: US prescribing information; 2022. https://dailymed.nlm.nih.gov/. Accessed 22 Mar 2023.

Sidonio RF Jr, Casiano S, Falk A, et al. Pharmacokinetic parameters of recombinant factor IX Fc fusion protein are not influenced by factor IX antigen levels in subjects from the phase 3 B-LONG trial. Haemophilia. 2022;29(1):404–7.

Article  PubMed  Google Scholar 

Mann DM, Stafford KA, Poon MC, et al. The function of extravascular coagulation factor IX in haemostasis. Haemophilia. 2021;27(3):332–9.

Article  PubMed  Google Scholar 

Astermark J, Wojciechowski P, Aballéa S, et al. Efficacy of rFIXFc versus rIX-FP for the treatment of patients with hemophilia B: matching-adjusted indirect comparison of B-LONG and PROLONG-9FP trials. J Blood Med. 2021;12:613–21.

Article  PubMed  PubMed Central  Google Scholar 

Pochopien M, Tytuła A, Toumi M, et al. Cost-effectiveness of recombinant factor IX Fc prophylaxis and recombinant factor IX on-demand treatment in patients with haemophilia B without inhibitors. Value Health. 2022;25(12S).

Zhou T, Wang S, Zhang Y, et al. Cost-effectiveness analysis of recombinant factor IX Fc fusion protein compared with recombinant factor IX for the treatment of moderate-severe to severe hemophilia B in China. Pediatr Blood Cancer. 2023:e30264.

McCue J, Osborne D, Dumont J, et al. Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein. Haemophilia. 2014;20(4):e327–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rath T, Baker K, Dumont J, et al. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol. 2015;35(2):235–54.

Article  CAS  PubMed  Google Scholar 

Peters RT, Low SC, Kamphaus GD, et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood. 2010;115(10):2057–64.

Article  CAS  PubMed  Google Scholar 

Diao L, Li S, Ludden T, et al. Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B. Clin Pharmacokinet. 2014;53(5):467–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Traets MJM, Fischer K, Uitslager N, et al. Real-life pharmacokinetics of rFVIII-Fc and rFIX-Fc. TH Open. 2020;4(4):e362–4.

Article  PubMed  PubMed Central  Google Scholar